Browsing Over 57 Sessions

Sort By

Illumina - Profiling Non-Small Cell Lung Cancer using Comprehensive Genomic Profiling (ID 98)

Time
08:45 - 10:15

AstraZeneca - From Breast Cancer Biology to Therapy (ID 101)

Time
08:45 - 10:15

MSD - Homologous Recombination Deficiency: BRCA and beyond (ID 99)

Time
08:45 - 09:50

Servier - The clinical value of mIDH1 inhibition in cholangiocarcinoma (ID 100)

Time
08:45 - 10:15

MSD - The Role of Biomarkers in Patient Management in Immuno-Oncology (ID 103)

Time
10:30 - 11:30

AstraZeneca - Re-evaluating the role of gBRCA in breast cancer (ID 104)

Time
10:30 - 12:00

ITM Isotopen Technologien München AG - A Global Perspective on the Management of Neuroendocrine Tumors – the Evolving Role of Targeted Radionuclide Diagnostics and Therapy (ID 102)

Time
10:30 - 12:00

Novartis - Unmet needs in oncogene-driven NSCLC: how do we close the gap? (ID 105)

Time
10:30 - 12:00

Bayer - Taking action in nmCRPC: Cases in the clinic (ID 108)

Time
18:45 - 20:15

MSD - Evolving Treatment Landscape in HNSCC  (ID 106)

Time
18:45 - 20:15

Merck - Current and future treatments for head and neck cancer (ID 109)

Time
18:45 - 20:15

Medscape - A Stepwise  Approach To Managing HR+/HER2- Early Breast Cancer: From Risk Assessment To Risk Management  (ID 107)

Time
18:45 - 20:15